---
title: "Humacyte - CW27 | 8-K: FY2025 Q1 Revenue: USD 517 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240008979.md"
datetime: "2025-05-13T11:37:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240008979.md)
  - [en](https://longbridge.com/en/news/240008979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240008979.md)
generator: "portal-rs"
---

# Humacyte - CW27 | 8-K: FY2025 Q1 Revenue: USD 517 K

Revenue: As of FY2025 Q1, the actual value is USD 517 K.

EPS: As of FY2025 Q1, the actual value is USD 0.28.

### Segment Revenue

-   Total revenue for the first quarter of 2025 was $517,000, with $147,000 from the initial U.S. commercial launch of Symvess and $370,000 from a research collaboration.

### Operational Metrics

-   Cost of goods sold for the first quarter of 2025 was $147,000, with no cost of goods sold reported for the first quarter of 2024.
-   Research and development expenses decreased to $15.4 million in the first quarter of 2025 from $21.3 million in the same period of 2024, primarily due to decreased materials costs and reduced clinical study costs.
-   General and administrative expenses increased to $8.1 million in the first quarter of 2025 from $5.3 million in the first quarter of 2024, mainly due to the U.S. commercial launch of Symvess.
-   Net income for the first quarter of 2025 was $39.1 million, compared to a net loss of $31.9 million in the first quarter of 2024, primarily due to the non-cash remeasurement of the contingent earnout liability.

### Cash Flow

-   The company reported cash, cash equivalents, and restricted cash of $113.2 million as of March 31, 2025.
-   Total net cash provided was $17.9 million for the first three months of 2025, compared to $35.1 million for the same period in 2024, with the decrease primarily due to the absence of a $20 million funding draw that occurred in 2024.

### Unique Metrics

-   Humacyte completed a public offering in March 2025, raising $46.7 million in net proceeds.
-   The company implemented cost reduction actions, including workforce reductions and deferred hiring, estimating net savings of approximately $13.8 million in 2025 and up to $38.0 million in 2026.

### Outlook / Guidance

-   Humacyte plans to continue expanding the commercial launch of Symvess and anticipates filing an Investigational New Drug (IND) application for the small-diameter ATEV in coronary artery bypass grafting later in 2025.
-   The company is on track to file a supplemental Biologics License Application (BLA) for ATEV in dialysis in 2026, following a major enrollment milestone in its V012 Phase 3 trial.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- ['It's Deceiving,' Says Top Investor About SpaceX Stock](https://longbridge.com/en/news/297357151.md)
- [Nvidia or Marvell: Only One AI Stock Is a Buy Following Earnings, Says Investor](https://longbridge.com/en/news/297348643.md)
- [Walmart's (WMT) Hidden Profit Engine Could Bring Back a $1 Trillion Valuation](https://longbridge.com/en/news/297324744.md)
- [McDonald's: Beyond the Crowded AI Trade, Is the Cheapest McDonald's in Five Years Worth Buying?](https://longbridge.com/en/news/297288911.md)
- [Hong Kong exchange to launch Shein derivatives after trading debut next week](https://longbridge.com/en/news/297273656.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**